Abbott Laboratories to pay $670 million to settle baby formula lawsuits

Abbott Laboratories has agreed to a sweeping settlement to resolve a mountain of high-profile legal claims regarding its specialized infant formulas. According to reporting from Finance — Abbott Laboratories to pay $670 million to settle cases, claims over its formula for premature babies, the manufacturer will pay $670 million to resolve a high-profile lawsuit alongside claims made on behalf of thousands of other families.

The litigation centers on allegations that cow's milk-based products designed for preterm infants cause necrotizing enterocolitis, a dangerous intestinal disease where the tissue lining the intestine becomes inflamed and dies. The multi-million-dollar accord follows an appeals court decision upholding a massive judgment against the company.

Media additions

The bulk settlement addresses the landmark Gill lawsuit, where a Missouri jury previously ordered the company to pay $495 million in damages after determining it failed to warn that its formula for preterm infants increased the risk for a bowel disease, according to Morningstar — Dow Jones Top Company Headlines at 11 PM ET: SpaceX Is Racking Up Wins in Washington | Layoffs .... That case originally went to trial in Missouri Circuit Court in St. Louis. The plaintiff, an Illinois resident, alleged her daughter developed necrotizing enterocolitis after receiving the feeding products as a premature infant. The child had about seventy-five percent of her intestine removed and suffered brain damage as a result of the illness, an attorney previously stated.

Despite the massive financial resolution, Abbott continues to face substantial legal exposure. The company still confronts seventeen hundred lawsuits across the country involving claims made on behalf of roughly twelve thousand seven hundred infants, as reported by Yahoo Finance.

Corporate leadership maintains that the resolution is not an admission of liability. In a news release, the company stated that it stands firmly by the safety of its products and their essential role in the care of preterm infants.

"While Abbott remains confident in the safety of these products and the science supporting them, the company believes these agreements are in its best long-term interest and represent a constructive step toward substantially resolving the overall litigation"

Abbott Laboratories, via Yahoo Finance

Attempts to reach attorneys for the plaintiff who secured the initial trial victory were not immediately successful.

The legal battles extend beyond a single company or court system. Manufacturers such as Mead Johnson Nutrition also face similar litigation centralized in federal court in Chicago, where bellwether trials are intended to guide the broader resolution of pending claims. Other disputes are playing out in state courts, with varying outcomes on verdicts and appellate reversals.

The litigation has previously triggered wider industry concerns. Abbott's chief executive officer had previously suggested that the company could pull the formula altogether because of the flood of litigation, alarming doctors who worry that would mean fewer nutritional options for babies born prematurely.

Medical professionals agree that mother's milk should always be the primary choice for infants born very prematurely. Yet experts note that not all premature babies have access to biological or donated breast milk, creating an essential clinical need for specialized formulas.

While research shows an association between consumption of cow's milk-based formula by preterm babies and higher rates of the intestinal disease, the exact underlying cause remains unclear, and some preterm babies who consume exclusively breast milk also develop the condition. Federal health agencies previously released a joint statement following an expert report, noting that conclusive evidence is lacking to state that preterm infant formula directly causes the condition.

In a separate legal development involving corporate polluters and state settlements, the state of New Hampshire recently received a multi-million-dollar payment from 3M as part of a nationwide resolution over toxic PFAS contamination in public drinking water systems, according to Unionleader, New Hampshire gets $7.27M in PFAS settlement payment from 3M. That payment brought the state's total recovery from multiple contamination settlements past forty-three million dollars, with funds directed toward public water systems to address ongoing environmental cleanup efforts.

What to watch next

• Pending finalization and court documentation regarding Abbott's $670 million settlement terms.
• The ongoing federal bellwether trial in Chicago involving Mead Johnson Nutrition.
• Future appellate rulings and state court proceedings concerning remaining infant formula claims across the country.

For more corporate developments and financial updates, visit our Business coverage.